Adam Crystal - Feb 6, 2024 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Signature
/s/ Douglas Barry, attorney-in-fact
Stock symbol
TNGX
Transactions as of
Feb 6, 2024
Transactions value $
-$105,395
Form type
4
Date filed
2/8/2024, 09:04 PM
Previous filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Sale -$53.9K -4.29K -3.35% $12.56 124K Feb 6, 2024 Direct F1, F2
transaction TNGX Common Stock Sale -$51.5K -4.08K -3.3% $12.62 119K Feb 7, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2 Represents the weighted average sales price per share. The shares sold at prices ranging from $12.22 to $12.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Represents the weighted average sales price per share. The shares sold at prices ranging from $12.43 to $12.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Remarks:

President, Research & Development